Back

BONESUPPORT appoints Kristina Ingvar to Executive Vice President Quality Management & Regulatory Affairs

Lund, Sweden, 15:00 CET, 18 December 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team. Kristina Ingvar starts with the company February 1, 2020 and will formally take on the position as the Executive Vice President Quality Management & Regulatory Affairs of the company from 1 April 2020, in connection with Carin Nilsson-Thorell’s retirement. Kristina has a medical degree from Lund University. She joins BONESUPPORT from Novo Nordisk, where her most recent role has been Global Program Vice President, Regulatory Affairs. During her 20-year long career Kristina has held various product, project and people management positions in the regulatory, quality, safety and medical areas. Kristina has worked closely with R&D and Manufacturing & Supply, as well as Sales & Marketing in both small and large companies.

“Kristina Ingvar is the right person to take on the responsibility for our regulatory and quality functions. Kristina’s experience in the field, together with her leadership and market-oriented thinking will be of great value to us. At the same time, I would like to extend a big thank you to Carin Nilsson-Thorell who has meant a lot to the company and its journey for many years and wish her all the best for the future” says Emil Billbäck, BONESUPPORT’s CEO.

About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

For more information contact:

BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70

Cord Communications
Charlotte Stjerngren
+46 (0)708 76 87 87

www.cordcom.se

 About Us

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void.BONESUPPORT’s bio-ceramic bone graft substitutes CERAMENT® BONE VOID FILLER (BVF), CERAMENT® G* and CERAMENT® V* are all based on the Company’s novel and proprietary technology platform.The Company’s research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of drugs and therapeutic agents. The Company currently has a pipeline of pre-clinical product candidates that have been designed to promote bone growth.BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker “BONEX” (ISIN code: SE0009858152). Further information is available at www.bonesupport.com*CERAMENT G: Not available in the United States, for investigational use only.CERAMENT V: Not available in the United States.BONESUPPORT™ and CERAMENT® are registered trademarks.


Source: Cision/BONESUPPORT